Horizon Pharma plc (HZNP) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($2.57 million) and the uptick to downtick ratio was 0.73. The transaction value on upticks was $6.94 million and on downticks, the transaction value was $9.51 million. In block trades, the transaction value of inflow done during uptick was $0.86 million. The transaction value of block trades during downticks was $3.07 million. The uptick to downtick block trade ratio was 0.28. The money flow was negative ($2.22 million), indicating the traders were booking profit on the price strength. Horizon Pharma plc (HZNP) rose $0.07 at $18.91, during intraday Tuesday , a rise of 0.37% over the previous days close.
Also, Equity Analysts at the Citigroup maintains the rating on Horizon Pharma plc (NASDAQ:HZNP). The brokerage firm has issued a Neutral rating on the shares. The Analysts at the ratings agency raises the price target from $18 per share to $21 per share. The rating by the firm was issued on August 9, 2016.
Horizon Pharma plc has dropped 15.1% in the last five trading days, however, the shares have posted positive gains of 0.64% in the last 4 weeks. Horizon Pharma plc is up 8.63% in the last 3-month period. Year-to-Date the stock performance stands at -12.28%.
Horizon Pharma plc (NASDAQ:HZNP): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $18.84 and $18.81 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $19.27. The buying momentum continued till the end and the stock did not give up its gains. It closed at $19.01, notching a gain of 0.90% for the day. The total traded volume was 4,041,093 . The stock had closed at $18.84 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Sherman Jeffrey W, officer (EVP and Chief Medical Officer) of Horizon Pharma Plc, had unloaded 2,900 shares at an average price of $20 in a transaction dated on August 2, 2016. The total value of the transaction was worth $58,000.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.